Home » Stocks » Galera Therapeutics

Galera Therapeutics, Inc. (GRTX)

Stock Price: $11.55 USD -1.26 (-9.84%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $11.73 +0.18 (1.56%) Oct 27, 6:44 PM

Stock Price Chart

Key Info

Market Cap 287.39M
Revenue (ttm) n/a
Net Income (ttm) -67.10M
Shares Out 24.88M
EPS (ttm) -173.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $11.55
Previous Close $12.81
Change ($) -1.26
Change (%) -9.84%
Day's Open 12.53
Day's Range 10.50 - 13.48
Day's Volume 432,186
52-Week Range 5.58 - 19.50

More Stats

Market Cap 287.39M
Enterprise Value 183.66M
Earnings Date (est) Dec 15, 2020
Ex-Dividend Date n/a
Shares Outstanding 24.88M
Float 9.98M
EPS (basic) 68.62
EPS (diluted) -173.09
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 92,301
Short Ratio 3.69
Short % of Float 0.92%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 7.33
Revenue n/a
Operating Income -64.56M
Net Income -67.10M
Free Cash Flow n/a
Net Cash 103.73M
Net Cash / Share 4.17
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -39.30%
ROE -166.59%
ROIC -77.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 3
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(55.84% upside)
Current: $11.55
Target: 18.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-50.69-24.26-24.09
Net Income-51.93-23.68-23.55
Shares Outstanding3.630.300.30
Earnings Per Share-16.31-98.42-93.59
Operating Cash Flow-46.66-22.17-23.41
Capital Expenditures-0.63-0.35-0.32
Free Cash Flow-47.29-22.51-23.73
Cash & Equivalents11281.5214.18
Total Debt0.83--
Net Cash / Debt11181.5214.18
Book Value69.61-105-76.11
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Galera Therapeutics, Inc.
Country United States
Employees 32
CEO J. Mel Sorensen

Stock Information

Ticker Symbol GRTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: GRTX
IPO Date November 7, 2019


Galera Therapeutics, a clinical-stage biotechnology company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is GC4419, a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase I clinical trial for the treatment of radiotherapy-induced esophagitis. It is also involved in developing GC4711, which is in Phase I clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is based in Malvern, Pennsylvania.